405 related articles for article (PubMed ID: 17469105)
21. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.
Sellam J; Rouanet S; Hendel-Chavez H; Abbed K; Sibilia J; Tebib J; Le Loët X; Combe B; Dougados M; Mariette X; Taoufik Y
Arthritis Rheum; 2011 Dec; 63(12):3692-701. PubMed ID: 22127692
[TBL] [Abstract][Full Text] [Related]
22. Gene expression profile in the salivary glands of primary Sjögren's syndrome patients before and after treatment with rituximab.
Devauchelle-Pensec V; Cagnard N; Pers JO; Youinou P; Saraux A; Chiocchia G
Arthritis Rheum; 2010 Aug; 62(8):2262-71. PubMed ID: 20506202
[TBL] [Abstract][Full Text] [Related]
23. Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment.
Muhammad K; Roll P; Einsele H; Dörner T; Tony HP
Arthritis Rheum; 2009 Aug; 60(8):2284-93. PubMed ID: 19644860
[TBL] [Abstract][Full Text] [Related]
24. Rituximab therapy in primary Sjögren's syndrome.
Alcântara C; Gomes MJ; Ferreira C
Ann N Y Acad Sci; 2009 Sep; 1173():701-5. PubMed ID: 19758218
[TBL] [Abstract][Full Text] [Related]
25. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
Vallerskog T; Heimbürger M; Gunnarsson I; Zhou W; Wahren-Herlenius M; Trollmo C; Malmström V
Arthritis Res Ther; 2006; 8(6):R167. PubMed ID: 17092341
[TBL] [Abstract][Full Text] [Related]
26. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.
Pollard RP; Abdulahad WH; Vissink A; Hamza N; Burgerhof JG; Meijer JM; Visser A; Huitema MG; Spijkervet FK; Kallenberg CG; Bootsma H; Kroese FG
Ann Rheum Dis; 2013 Jan; 72(1):146-8. PubMed ID: 22851468
[No Abstract] [Full Text] [Related]
27. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma.
Pijpe J; van Imhoff GW; Vissink A; van der Wal JE; Kluin PM; Spijkervet FK; Kallenberg CG; Bootsma H
Ann Rheum Dis; 2005 Jun; 64(6):958-60. PubMed ID: 15576414
[TBL] [Abstract][Full Text] [Related]
28. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody.
Sidner RA; Book BK; Agarwal A; Bearden CM; Vieira CA; Pescovitz MD
Hum Antibodies; 2004; 13(3):55-62. PubMed ID: 15598985
[TBL] [Abstract][Full Text] [Related]
29. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
Cambridge G; Stohl W; Leandro MJ; Migone TS; Hilbert DM; Edwards JC
Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
[TBL] [Abstract][Full Text] [Related]
30. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.
Anolik JH; Barnard J; Cappione A; Pugh-Bernard AE; Felgar RE; Looney RJ; Sanz I
Arthritis Rheum; 2004 Nov; 50(11):3580-90. PubMed ID: 15529346
[TBL] [Abstract][Full Text] [Related]
31. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
Teng YK; Levarht EW; Toes RE; Huizinga TW; van Laar JM
Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852
[TBL] [Abstract][Full Text] [Related]
32. Reconstitution of peripheral allospecific CD19+ B-cell subsets after B-lymphocyte depletion therapy in renal transplant patients.
Kopchaliiska D; Zachary AA; Montgomery RA; Leffell MS
Transplantation; 2009 May; 87(9):1394-401. PubMed ID: 19424042
[TBL] [Abstract][Full Text] [Related]
33. T regulatory cells are markedly diminished in diseased salivary glands of patients with primary Sjögren's syndrome.
Li X; Li X; Qian L; Wang G; Zhang H; Wang X; Chen K; Zhai Z; Li Q; Wang Y; Harris DC
J Rheumatol; 2007 Dec; 34(12):2438-45. PubMed ID: 18050367
[TBL] [Abstract][Full Text] [Related]
34. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
Seror R; Sordet C; Guillevin L; Hachulla E; Masson C; Ittah M; Candon S; Le Guern V; Aouba A; Sibilia J; Gottenberg JE; Mariette X
Ann Rheum Dis; 2007 Mar; 66(3):351-7. PubMed ID: 16950808
[TBL] [Abstract][Full Text] [Related]
35. Depletion of peripheral blood B cells with Rituximab and phenotype characterization of the recovering population in a patient with follicular lymphoma.
Abulayha AM; Tabal SA; Shawesh EI; Elbasir MA; Elbanani AS; Lamami YM; Bredan A
Leuk Res; 2010 Mar; 34(3):307-11. PubMed ID: 19580998
[TBL] [Abstract][Full Text] [Related]
36. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.
Kim SJ; Lee SJ; Choi IY; Park Y; Choi CW; Kim IS; Yu W; Hwang HS; Kim BS
Eur J Haematol; 2008 Sep; 81(3):177-84. PubMed ID: 18510703
[TBL] [Abstract][Full Text] [Related]
37. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
[TBL] [Abstract][Full Text] [Related]
38. Dysregulation of chemokine receptor expression and function by B cells of patients with primary Sjögren's syndrome.
Hansen A; Reiter K; Ziprian T; Jacobi A; Hoffmann A; Gosemann M; Scholze J; Lipsky PE; Dörner T
Arthritis Rheum; 2005 Jul; 52(7):2109-19. PubMed ID: 15986367
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
40. B-cell-activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy.
de la Torre I; Moura RA; Leandro MJ; Edwards J; Cambridge G
Ann Rheum Dis; 2010 Dec; 69(12):2181-8. PubMed ID: 20581016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
